Cardinal Health, a healthcare services company, is expanding its manufacturing facility in Indianapolis to meet the growing demand for nuclear medical products known as radiopharmaceuticals. The company has already invested over $50 million in the project, which includes the construction of a clean room for the production of actinium 225, an isotope used in targeted cancer treatments. Cardinal Health is not the only company investing in the radiopharmaceutical industry in central Indiana; pharmaceutical giants like Eli Lilly, Novartis, and Bristol Myers Squibb have also made significant acquisitions and expansions in the region. Indiana's central location and logistical advantages, coupled with the expertise of Purdue University's nuclear pharmacy program, have contributed to the growth of the industry in the area. The demand for radiopharmaceuticals is expected to continue to rise, as these drugs provide more precise and effective cancer treatments compared to traditional chemotherapy.
Fri, 17 May 2024 21:20:00 GMT | Inside INdiana Business